
This is the peer reviewed version of the following article:

Original:


Published:

DOI:10.1080/14712598.2016.1198765

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)
Switch from Infliximab to Infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases.

Stefano Gentileschi¹, Cristiana Barreca¹, Francesca Bellisai¹, Giovanni Biasi¹, Maria Giuseppina Brizi¹, Renato de Stefano¹, Marta Fabbroni¹, Elena Frati¹, Enrico Selvi¹, Antonio Vitale¹, Luca Cantarini¹, Bruno Frediani¹, Mauro Galeazzi¹, Antonella Fioravanti¹

¹Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

Corresponding author:
Luca Cantarini, MD, PhD; Rheumatology Unit, Policlinico Le Scotte, University of Siena, Viale Bracci 1, 53100 Siena, Italy; Phone: +39 0577/586778; Fax: +39 0577/318462. Email: cantariniluca@hotmail.com

Running Title: efficacy of the switch from originator to biosimilar

Key words: infliximab; biosimilar; switch; spondyloarthritis; rheumatoid arthritis
Dear Editor-in-Chief

We read with great interest the manuscript by Nikipherou E et al. describing the effectiveness of infliximab-biosimilar CT-P13 (INB) used as a switch from Remicade (Infliximab) in patients with different established rheumatic diseases [1]. Thirty-nine patients on Infliximab (INX) were switched to biosimilar after a mean time (SD) of 4.1 (2.3) years. The authors reported that INB clinical effectiveness, during the first year of switching, was comparable to INX in both the patient-reported outcomes and disease-activity measures, with no immediate safety signals. Eleven patients (28.2%) discontinued INB due to INX antibodies detected prior to INB infusion (3/11); latent tuberculosis (1/11); new-onset neurofibromatosis (1/11); subjective reasons with no objective deterioration of disease (6/11). The authors suggested that subjective reasons, such as negative expectations, played a key role among INB discontinuations.

In this regard, we report herein our experience in a cohort of 23 patients followed in our Unit for different rheumatic diseases and switched, for local regulatory issues, to INB (Inflectra®) after a mean time (SD) of 71.65 (44.40) months on INX (Remicade®). More in detail, 11 out of 23 had psoriatic arthritis (7 with peripheral and 4 with axial involvement), 8/23 ankylosing spondylitis, 2/23 rheumatoid arthritis, 2/23 Crohn’s disease and associated axial spondyloarthritis and 1/23 Behçet’s disease and associated axial spondyloarthritis. At the time of the switch, all of the patients were in complete disease remission on INX at a dose of 5mg/kg every 8 weeks. After a mean time of 1.71 months (range, 1-2) from the start of INB a disease relapse occurred in 7 out of 23 patients (30.43%). Their mean (SD) duration of previous INX treatment was 62.28 (49.95) months. Table 1 summarizes the clinical, demographic and therapeutic data of the 7 subjects unresponsive to INB. INB was then suspended and IFX was re-administered in all 7 patients at a dose of 5mg/kg every 8 weeks, in association with a tapering dose of oral corticosteroids. In 5/7, the readministration of INX promptly led to a remarkable clinical improvement (4/5), or at least a partial one (1/5), with a significant decrement of the disease activity indexes. No amelioration was observed in 2/7 subjects.
Among the 16 patients that were still on treatment with INB, 7 of them were under close observation and monitoring for uveitis relapse (1/7); recurrence of psoriatic lesions (1/7); arthralgia (4/7); referred worsening of global quality of life (1/7). No changes in the response to treatment were observed in 9 out of 23 subjects (39.13%). INB was well tolerated and no adverse events were noted.

In PLANETAS and PLANETRA studies INB demonstrated equivalent efficacy to INX at 30-week follow-up, with a comparable pharmacokinetic profile and immunogenicity both in patients affected by Ankylosing Spondylitis (AS) and Rheumatoid Arthritis (RA) [2, 3]. INB efficacy and safety have been confirmed also in the extension of the PLANETAS study in AS at 54-week follow-up [4]. Nevertheless, data on the effectiveness of the switch from INX to INB in patients in a stable disease remission while on IFX are scarce, and future studies are needed. For the above reason, real-life data should be welcome, even though from uncontrolled series, until further trials are performed. In our cohort of patients, 30% of subjects switched from IFX to INB while in disease remission showed a rapid worsening of disease activity indexes. Moreover, 30% of patients still on treatment with INB were under evaluation for the potential reduction of the interval between INB administrations either the potential increase of INB dosage or a further switch from INB to IFX, due to a suspected lack of efficacy. Overall, it is unlikely that in our cohort of patients, only subjective reasons have played a role in the poor outcome observed in most subjects. Indeed, we did not observe any change in the response to treatment in only 40% of cases. Limitations of our study were the small number of patients, the absence of a control group and the short-term follow-up. Until data from controlled ad-hoc studies are available, the interchangeability of IFX with INB, still remains a debated issue. For this reason, it is our opinion that a large-scale switch based on economic and regulatory affairs should be avoided, because of the loss of efficacy in a not negligible percentage of previously responsive patients.
Declaration of Interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties

References


### Table 1. Clinical, demographic and therapeutic characteristics of the refractory patient

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Gender</th>
<th>HLA B (B27/B51)</th>
<th>Diagnosis</th>
<th>Concomitant diseases and/or extra articular manifestations</th>
<th>Age at disease Onset</th>
<th>Age at diagnosis</th>
<th>Previous treatments</th>
<th>Duration of previous IFX treatment (months)</th>
<th>Concomitant treatments (during IFX and INB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>56</td>
<td>F</td>
<td>( - / + )</td>
<td>Axial SpA</td>
<td>Behçet’s Disease</td>
<td>41</td>
<td>51</td>
<td>Etanercept 50mg/w Adalimumab 40mg/2w MTX, PDN NSAIDs</td>
<td>20</td>
<td>MTX, NSAIDs</td>
</tr>
<tr>
<td>2</td>
<td>23</td>
<td>M</td>
<td>( + / - )</td>
<td>Axial SpA</td>
<td>Crohn’s Disease</td>
<td>23</td>
<td>23</td>
<td>NSAIDs SLZ, PDN</td>
<td>3</td>
<td>none</td>
</tr>
<tr>
<td>3</td>
<td>49</td>
<td>M</td>
<td>n.k</td>
<td>Axial SpA</td>
<td>none</td>
<td>30</td>
<td>36</td>
<td>NSAIDs MTX, PDN</td>
<td>63</td>
<td>NSAIDs</td>
</tr>
<tr>
<td>4</td>
<td>64</td>
<td>M</td>
<td>( + / - )</td>
<td>Peripheral SpA</td>
<td>Psoriasis</td>
<td>44</td>
<td>46</td>
<td>NSAIDs MTX, SLZ, PDN</td>
<td>136</td>
<td>MTX</td>
</tr>
<tr>
<td>5</td>
<td>60</td>
<td>F</td>
<td>n.k</td>
<td>Axial SpA</td>
<td>Crohn’s Disease</td>
<td>46</td>
<td>50</td>
<td>NSAIDs SLZ, PDN</td>
<td>63</td>
<td>NSAIDs</td>
</tr>
<tr>
<td>6</td>
<td>48</td>
<td>M</td>
<td>( - / + )</td>
<td>Axial SpA</td>
<td>Psoriasis</td>
<td>38</td>
<td>45</td>
<td>NSAIDs Etanercept 50mg/w PDN</td>
<td>19</td>
<td>MTX</td>
</tr>
<tr>
<td>7</td>
<td>41</td>
<td>M</td>
<td>( + / - )</td>
<td>Axial SpA</td>
<td>Psoriasis</td>
<td>14</td>
<td>28</td>
<td>NSAIDs MTX</td>
<td>132</td>
<td>NSAIDs</td>
</tr>
</tbody>
</table>

**List of abbreviations:** M, male; F, female; W, week; MTX, methotrexate; PDN, prednisone; NSAIDs, non-steroidal anti-inflammatory drugs; SLZ, sulphasalazine; IFX, Infliximab